Selecta Biosciences (NASDAQ:SELB) reported Q4 EPS of $0.04, $0.11 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $11.68 million.
Selecta Biosciences (NASDAQ:SELB) reported Q4 EPS of $0.04, $0.11 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $11.68 million.